Anxian Yuan China Holdings Limited (0922) AI Stock Analysis

• Market Cap: HK$324.32M
• Dividend Yield: 7.43%
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): 6.4
• Beta (1Y): 0.16
• Revenue Growth: -16.88%
• EPS Growth: -11.54%
• Country: HK
• Employees: 226
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): 0.01
• Shares Outstanding: 2,221,363,000
• 10 Day Avg. Volume: 1,961,400
• 30 Day Avg. Volume: 1,335,236
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The stock's overall score is driven by its strong valuation, with an attractive P/E ratio and high dividend yield. However, financial performance is challenged by declining revenue growth and profitability. Technical analysis indicates weak momentum, which could limit short-term price appreciation.

Anxian Yuan China Holdings Limited Business Overview & Revenue Model

Company Description

Anxian Yuan China Holdings Limited (0922) is a Hong Kong-based investment holding company that primarily operates in the sectors of healthcare and consumer products. The company focuses on the development, manufacturing, and distribution of healthcare-related products, particularly in traditional Chinese medicine, as well as a range of consumer goods aimed at improving quality of life. Anxian Yuan aims to leverage the growing demand for natural and wellness products in both domestic and international markets.

How the Company Makes Money

Anxian Yuan generates revenue through multiple streams, primarily from the sale of its healthcare products and consumer goods. The company has established partnerships with various suppliers and distributors to enhance its market reach. Its business model includes direct sales to consumers, as well as wholesale distribution to retail outlets. Additionally, the company benefits from the increasing popularity of traditional Chinese medicine, which allows it to capitalize on the growing trend of holistic health solutions. Strategic collaborations and joint ventures with other companies in the healthcare sector also contribute to its revenue, enabling Anxian Yuan to expand its product offerings and market penetration.

Anxian Yuan China Holdings Limited Financial Statement Overview

Summary

Anxian Yuan China Holdings Limited demonstrates strong gross profit margins and a solid balance sheet with low leverage. However, declining revenue growth and net profit margins, along with reduced return on equity, highlight challenges in maintaining profitability and growth. The cash flow position is stable, but efficiency in cash generation has shown some decline. Overall, the company is financially stable but faces challenges in sustaining growth and profitability.

Income Statement

The company has maintained a strong gross profit margin over the years, consistently above 70%, indicating efficient cost management. However, the net profit margin has shown a declining trend from 30.8% in 2023 to 21.6% in 2025, reflecting potential challenges in maintaining profitability. The revenue growth rate has been negative in the last two years, with a significant drop of 5.5% in 2025, which is a concern for future revenue generation.

Balance Sheet

The company has a very low debt-to-equity ratio, decreasing from 0.146 in 2021 to 0.048 in 2025, indicating strong financial stability and low leverage risk. However, the return on equity has decreased from 10.8% in 2023 to 5.4% in 2025, suggesting reduced efficiency in generating profits from shareholders' equity. The equity ratio remains strong, indicating a solid capital structure.

Cash Flow

The free cash flow growth rate has been positive in 2025 at 8.6%, showing improvement in cash generation. However, the operating cash flow to net income ratio has decreased from 1.17 in 2023 to 0.44 in 2025, indicating a potential decline in cash flow efficiency. The free cash flow to net income ratio remains strong, suggesting good cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	250.25M	236.43M	284.43M	340.53M	310.95M	298.74M
Gross Profit	181.84M	172.98M	207.73M	251.41M	220.18M	212.94M
EBITDA	97.03M	98.85M	106.40M	165.78M	135.67M	139.97M
Net Income	49.19M	51.08M	57.82M	104.92M	73.13M	80.30M
Balance Sheet
Total Assets	1.30B	1.28B	1.28B	1.33B	1.34B	1.34B
Cash, Cash Equivalents and Short-Term Investments	323.90M	329.70M	339.43M	340.53M	209.87M	255.94M
Total Debt	33.55M	44.59M	17.74M	45.27M	49.45M	131.43M
Total Liabilities	326.38M	309.91M	296.46M	325.89M	335.74M	405.37M
Stockholders Equity	936.70M	937.65M	942.97M	970.33M	965.29M	897.19M
Cash Flow
Free Cash Flow	62.16M	67.51M	84.81M	184.43M	66.84M	104.58M
Operating Cash Flow	67.87M	72.45M	91.64M	186.51M	69.14M	109.02M
Investing Cash Flow	-45.65M	-129.85M	57.77M	-60.79M	-2.63M	-7.41M
Financing Cash Flow	-44.12M	-12.69M	-79.74M	-33.65M	-131.30M	63.93M

Anxian Yuan China Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0922, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.03 is Neutral, neither overbought nor oversold. The STOCH value of 32.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0922.

Anxian Yuan China Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0922	65 Neutral	HK$324.32M	6.43	5.43%	7.43%	-16.88%	-11.54%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
1448	61 Neutral	$6.58B	19.03	-3.58%	18.25%	-28.00%	-129.57%
6966	56 Neutral	HK$495.00M	―	-3.06%	1.12%	-38.66%	-161.86%
8296	48 Neutral	HK$37.33M	―	-3.96%	―	15.60%	62.35%

Anxian Yuan China Holdings Limited Corporate Events

Anxian Yuan China Holdings Limited Updates Nomination Committee Terms

Anxian Yuan China Holdings Limited has outlined the terms of reference for its Nomination Committee, which was established in 2012. The committee is responsible for reviewing the board’s structure, size, and composition to ensure alignment with the company’s corporate strategy and shareholder value. The committee’s operations include holding at least one meeting annually, with a majority of independent non-executive directors, and maintaining a board skills matrix to guide its recommendations.

Anxian Yuan China Holdings Announces Successful AGM Resolutions

Anxian Yuan China Holdings Limited announced the successful passing of all resolutions at its Annual General Meeting held on 8 September 2025. The resolutions included the adoption of financial statements, declaration of a final dividend, re-election of directors, re-appointment of auditors, and granting of mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued operational stability and strategic flexibility.

Anxian Yuan China Holdings Announces Contingency Plans for AGM Amid Typhoon Threat

Anxian Yuan China Holdings Limited has announced a contingency plan for its Annual General Meeting (AGM) scheduled on 8 September 2025, due to the potential impact of Typhoon Signal No. 3 in Hong Kong. The company has outlined several scenarios for rescheduling the AGM depending on the severity of the weather conditions, ensuring that all resolutions and proxy forms remain valid for any rescheduled meeting. Shareholders are advised to assess their own safety when deciding to attend the AGM under adverse weather conditions.

Anxian Yuan China Holdings Announces 2025 AGM Agenda

Anxian Yuan China Holdings Limited has announced the notice for its upcoming annual general meeting scheduled for September 8, 2025. The meeting will address several key resolutions, including the adoption of financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks approval to empower its directors to allot and issue shares within specified limits, which could impact the company’s capital structure and shareholder value.